마이코박테리아 세포벽 분획 면역조절제

면역자극제 / 생물학적 제제

**마이코박테리아 세포벽 분획 면역조절제**는 종양 및 특정 감염에 대항하여 환자의 면역 체계를 자극하기 위해 수의학에서 사용되는 생물학적 제제입니다. * **개**의 경우, 혼합 유선 종양 및 유선 선암의 면역 요법을 위한 국소 침윤 주사제로 사용됩니다. * **말**의 경우, 유사종(국소 침윤), 정맥 주사(IV)를 통한 말 호흡기 질환 증후군(ERDC), 그리고 *Streptococcus zooepidemicus*에 의해 발생한 말 자근내막염(IV 또는 자근 내 주입)을 치료하는 데 사용됩니다. > **임상 팁:** 이 약물은 면역조절제이므로, 그 효능은 환자가 정상적인 면역 체계를 갖추고 있는지에 전적으로 달려 있습니다. 국소(종양 내) 효능은 문헌에 보고되어 있지만, 전신적인 효능은 그다지 명확하게 확립되지 않았습니다.

작용 기전: The drug exerts a non-specific immune stimulatory effect, primarily targeting **cell-mediated immune mechanisms** and **macrophage activation**. * **Macrophage activation** → Release of **Interleukin-1 (IL-1)** → Cascade of immune responses targeting abnormal cells (tumors) or pathogens. * Requires a competent, functional immune system to be effective.

동물 종별 용량

Horses

Immunotherapy of sarcoids · Dosage varies with tumor size, but 1 mL should be considered a minimum dose. Infiltrate entire tumor and a small region of adjacent and underlying tissue. · Intratumoral · Repeat treatment every 1-3 weeks. · Discontinue if no response after 4 treatments · Large pedunculated sarcoids should be de-bulked by partial excision prior to treatment. Use no larger than a 20-gauge needle. Inject quickly as emulsion separates rapidly.
Immunotherapeutic agent for the treatment of Equine Respiratory Disease Complex (ERDC) · 1.5 mL (one syringe) · IV · May be repeated in 1-3 weeks · Inject into the jugular vein.
Aid in the treatment of equine metritis caused by Streptococcus zooepidemicus · 1.5 mL (one syringe) · IV · Once during the early estrus period · Inject into the jugular vein.
Aid in the treatment of equine metritis caused by Streptococcus zooepidemicus · Dilute 1.5 mL of Settle in sterile LRS, normal saline, water for injection or semen extender to provide a final volume of 25-50 mL. · Intrauterine · Once · Aseptically administer the diluted solution into the uterus using a sterile catheter.

Dogs

Immunotherapy of mixed mammary tumor and mammary adenocarcinoma · Dosage varies with tumor size, but 1 mL should be considered a minimum dose. Infiltrate entire tumor and a small region of adjacent and underlying tissue. · Intratumoral · Once, 2-4 weeks before surgery. If surgery is not to be used, repeat treatment every 1-3 weeks. · Discontinue if no response after 4 treatments · Using no larger than a 20-gauge needle. Be certain the emulsion is mixed thoroughly and inject quickly as emulsion can separate rapidly. Additional anesthetics or analgesics may be used for pain.

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

IntratumoralIVIntrauterine

금기

Prior hypersensitivity to mycobacterial cell wall compounds
Active mycobacterial infections

이상반응

Transient fever
Depression or drowsiness
Decreased appetite
Localized pain and tenderness at injection site
Tumor necrosis and draining (expected therapeutic effect but can be an adverse event)
Hypersensitivity or Anaphylaxis
Severe respiratory inflammatory reactions (reported in horses)

약물 상호작용

Corticosteroids, ACTH, Immunosuppressive drugs (e.g., cyclosporine) · May reduce the effectiveness of mycobacterial cell wall immunostimulants

모니터링

Clinical Efficacy (tumor size, metritis improvement, or respiratory infection improvement)
Adverse Effects (fever, local reactions, appetite)

과용량

No information was located regarding overdosage or acute toxicity.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.